San Francisco Superior Court where the plaintiff alleges the drug Oxbryta contributed to the onset of a vaso-occlusive crisis (VOC) as well as significant pain and swelling throughout the body.
The decision was based on preclinical data demonstrating that masitinib was able to prevent vaso-occlusive crises (VOCs), a common complication of the disease, and increase survival in a mouse model ...
Plaintiff Tirrell Allen said he experienced a higher rate of vaso-occlusive crisis, a disease complication, after using the medication, according to the complaint filed Thursday in the US District ...
At least 15 people were killed in Damascus, according to Syrian state media. The Israeli military said it had “inflicted significant damage” to a Palestinian Islamic Jihad command center. By ...
Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, today announced the launch of its new Global Therapy Innovations business unit, designed to integrate disease expertise ...
AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, announced that the European Patent Office has issued a Notice of ...
Stay updated on Beam Therapeutics Inc.'s latest advancements in Sickle Cell Disease and alpha-1 antitrypsin deficiency treatments. Click for my BEAM stock update.
Sickle cell disease 2 is an important but commonly forgotten risk factor. Diagnosis of sickle cell disease can be delayed as sickle-cell-related back pain might be misconstrued as an indicator of a ...